Novavax, Inc. (Novavax), is a clinical stage biopharmaceutical company. The Company focuses on developing recombinant vaccines. The Company�s technology platform is based on recombinant vaccine technology that includes the virus-like particles (VLPs). The Company's vaccine candidates are genetically engineered three-dimensional nanostructures, which incorporate immunologically important recombinant proteins. The Company's product pipeline focuses on a variety of infectious diseases and the Company's vaccine candidates have completed clinical trials that target pandemic influenza (H5N1), seasonal influenza and respiratory syncytial virus (RSV). The Company�s joint venture, CPL Biologics Private Limited, develops a rabies vaccine candidate that is genetically engineered by Novavax. CPL Biologics Private Limited completed initial pre-clinical immunogenicity studies on this new vaccine candidate and is progressing with pre-clinical toxicology studies.